SCHEMBL8359232

SCHEMBL8359232

Cc1nc(C(=O)O)c2n1-c1ccccc1C(c1ccccc1)=NC2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA5 P31644 4/20 0.49
GABRA2 P47869 4/20 0.49
GABRB2 P47870 4/20 0.49
GABRA1 P14867 3/20 0.49
GABRG2 P18507 2/20 0.49
GABRB3 P28472 2/20 0.49
GABRA3 P34903 2/20 0.49
CCKBR P32239 1/20 0.49
BRD4 O60885 3/20 0.46
KDM4E B2RXH2 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
BRD2 P25440 1/20 0.43
BRD3 Q15059 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
POLB P06746 1/20 0.42
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
CNR1 P21554 1/20 0.41
OPRK1 P41145 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11016370 0.87 GABRA1 (0.46) GABRA5GABRA2GABRB2GABRA1GABRG2
SCHEMBL7310152 0.87 OPRK1 (0.60) GABRA5GABRA2GABRB2GABRA1GABRG2
SCHEMBL7721824 0.84 GABRA1 (0.62) GABRA5GABRA2GABRB2GABRA1GABRG2
SCHEMBL7308087 0.83 LMNA (0.58) GABRA5GABRA2GABRB2GABRA1GABRG2
SCHEMBL1313752 0.78 GABRA1 (0.60) GABRA5GABRA2GABRB2GABRA1GABRG2
SCHEMBL7307080 0.78 OPRK1 (0.58) GABRA5GABRA2GABRB2GABRA1GABRG2
SCHEMBL7316446 0.77 OPRK1 (0.57) GABRA5GABRA2GABRB2GABRA1GABRG2
SCHEMBL9565440 0.77 GABRA5 (0.45) GABRA5GABRA2GABRB2GABRA1GABRG2
SCHEMBL11016146 0.77 GABRA1 (0.45) GABRA5GABRA2GABRB2GABRA1GABRG2
SCHEMBL1311112 0.77 OPRK1 (0.63) GABRA5GABRA2GABRB2GABRA1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100261711-A1 SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES WISYS TECHNOLOGY FOUNDATION (US) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261711-A1 SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES GABRA5, GABRA6, GABRA2 GABRA5 1/4885GABRA2 3/4885GABRB2 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.